SCHEMBL3205487

SCHEMBL3205487

Brc1cccc2nnnn12

nearest known ligand 0.41

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
AHR P35869 2/20 0.41
ALDH1A1 P00352 2/20 0.32
CYP11B2 P19099 1/20 0.31
L3MBTL1 Q9Y468 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8977852 0.74 CHEK1 (0.34) ALDH1A1L3MBTL1
SCHEMBL14672809 0.74 KMT2A (0.33) ALDH1A1L3MBTL1
SCHEMBL3209050 0.74 CYP11B2 (0.37) ALDH1A1CYP11B2L3MBTL1
SCHEMBL18078709 0.69 EGLN2 (0.53) ALDH1A1
SCHEMBL7915878 0.69 ALDH1A1 (0.33) ALDH1A1L3MBTL1
SCHEMBL9769233 0.67 KMT2A (0.33) ALDH1A1
SCHEMBL9769333 0.66 TSHR (0.31)
SCHEMBL1187776 0.66
SCHEMBL3303841 0.65 AHR (0.58) AHRCYP11B2
SCHEMBL18077056 0.65 EGLN2 (0.53)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100047321-A1 SILVER ANTIMICROBIAL COMPOSITION AND USE EASTMAN KODAK COMPANY 2010-02-25 US claimed
WO-2010021662-A2 SILVER ANTIMICROBIAL COMPOSITION AND USE EASTMAN KODAK COMPANY (US) 2010-02-25 WO claimed
US-20110293683-A1 Silver antimicrobial composition with extended shelf-life CERION TECHNOLOGY, INC. 2011-12-01 US disclosed
US-20100047321-A1 SILVER ANTIMICROBIAL COMPOSITION AND USE EASTMAN KODAK COMPANY 2010-02-25 US disclosed
WO-2010021662-A2 SILVER ANTIMICROBIAL COMPOSITION AND USE EASTMAN KODAK COMPANY (US) 2010-02-25 WO disclosed
EP-1173170-A4 PYRROLIDINE MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY MERCK & CO INC (US) 2002-05-29 EP disclosed
EP-1173170-A1 PYRROLIDINE MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY Merck & Co., Inc. (US) 2002-01-23 EP disclosed
US-6265434-B1 ANTIINFLAMMATORY AGENTS MERCK & CO., INC. 2001-07-24 US disclosed
WO-2000059503-A1 PYRROLIDINE MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY MERCK & CO., INC. (US) 2000-10-12 WO disclosed
US-5210014-A Benzimidazole carbocyanine dyes, storage stability EASTMAN KODAK COMPANY (US) 1993-05-11 US disclosed
EP-0506077-A1 Mid-green sensitizing dyes for photographic materials EASTMAN KODAK COMPANY (US) 1992-09-30 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110293683-A1 Silver antimicrobial composition with extended shelf-life AMPD1, GMPS, GDA AHR 791/4885ALDH1A1 200/4885CYP11B2 4422/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.